No Data
ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial
Express News | ZyVersa Therapeutics Q3 2024 GAAP EPS $(2.43) Beats $(3.70) Estimate
Express News | Zyversa Therapeutics - Qtrly Loss per Share $2.43
ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Press Release: ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
Express News | Zyversa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update
No Data
No Data
Paddyal : very strange.. it is tanking even with this good news
Trytosaveabit OP Paddyal : Big short low volume! Plus some taking profit from bag holding
Paddyal : I am stuck!! Will it even go up?what's your opinion?
Trytosaveabit OP Paddyal : It’s all volume/market interest! Gotta see! Wish I could answer that.